{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:58:39Z","timestamp":1787068719685,"version":"build-2736575974"},"reference-count":11,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1364,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1998,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Widely variable\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      eradication rates have been reported with omeprazole\/amoxycillin dual therapy. We present the first US double\u2010blind, controlled trials of this dual therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Three separate studies were performed: Studies 1 and 2 included patients with an active duodenal ulcer and Study 3 included patients with a documented history of duodenal ulcer.\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication regimens in all studies were omeprazole plus amoxycillin vs. omeprazole vs. amoxycillin for 2\u2003weeks. Doses in Study 1 were omeprazole 40\u2003mg b.d. and amoxycillin 500\u2003mg t.d.s., and in Studies 2 and 3 they were omeprazole 20\u2003mg b.d. and amoxycillin 1\u2003g t.d.s. Endoscopic biopsy tests were used for\n                      <jats:italic>H. pylori<\/jats:italic>\n                      diagnosis, and testing for\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication was done at least 4\u2003weeks after the completion of therapy. Amoxycillin sensitivities were performed in Study 2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Intention\u2010to\u2010treat (ITT) and per protocol (PP) analyses showed that eradication rates with omeprazole\/amoxycillin [ITT: 39%, 40%, 46% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2003=\u200372, 62, 48); PP: 50%, 46%, 54% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2003=\u200354, 52, 37)] were significantly greater than monotherapy with either omeprazole (ITT: 0\u20134%; PP: 0\u20135%) or amoxycillin (ITT: 2\u20135%; PP: 0\u201311%). No patients taking the dual therapy discontinued therapy due to adverse events. Amoxycillin resistance was not seen at baseline (\n                      <jats:italic>n<\/jats:italic>\n                      \u2003=\u200376) or after amoxycillin therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2003=\u200356).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Omeprazole\/amoxycillin dual therapy is well tolerated but the eradication rate which can be expected in the USA is at best about 50%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1046\/j.1365-2036.1998.00303.x","type":"journal-article","created":{"date-parts":[[2003,3,10]],"date-time":"2003-03-10T22:36:26Z","timestamp":1047335786000},"page":"377-382","source":"Crossref","is-referenced-by-count":9,"title":["US double\u2010blind, controlled trials of omeprazole and amoxycillin for treatment of\n                    <i>Helicobacter pylori<\/i>"],"prefix":"10.1111","volume":"12","author":[{"family":"Laine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Suchower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ronca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"491","article-title":"Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori","volume":"88","author":"Labenz J","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_3_2","article-title":"Do physicians from different countries treat H. pylori positive ulcer disease differently; a comparison between America and Germany","volume":"39","author":"Breuer T","year":"1996","journal-title":"Gut"},{"key":"e_1_2_6_4_2","first-page":"1407","article-title":"Limited efficacy of omeprazole\u2010based dual therapy and triple therapy for Helicobacter pylori: a randomized trial employing \u2018optimal\u2019 dosing","volume":"90","author":"Laine L","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_5_2","first-page":"1411","article-title":"Treatment of Helicobacter pylori infection with omeprazole\u2013amoxicillin combination therapy versus ranitidine\/sodium bicarbonate\u2013amoxicillin","volume":"90","author":"Al\u2010Assi MT","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_6_2","first-page":"1415","article-title":"Variability with omeprazole\u2013amoxicillin combinations for treatment of Helicobacter pylori infection","volume":"90","author":"Graham KS","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_7_2","article-title":"In vitro susceptibility of pre\u2010treatment isolates of Helicobacter pylori from 2 multicenter United States clinical trials","volume":"110","author":"Weissfeld AS","year":"1996","journal-title":"Gastroenterology"},{"key":"e_1_2_6_8_2","article-title":"Explanation for variability of omeprazole amoxicillin therapy? Tolerance of H. pylori to amoxycillin","volume":"112","author":"Dore MP","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_9_2","article-title":"Antimicrobial susceptibility of H. pylori in Canada to three key antibiotics: metronidazole, clarithromycin, and amoxicillin","volume":"112","author":"Fedorak R","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_10_2","article-title":"Susceptibility of Helicobacter pylori to clarithromycin and amoxicillin in U.S.","volume":"112","author":"Weissfeld A","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.140316000.x"},{"key":"e_1_2_6_12_2","article-title":"Triple vs. dual therapy with lansoprazole (L), clarithromycin (C) and\/or amoxicillin (A) in the eradication of Helicobacter pylori","volume":"91","author":"Schwartz H","year":"1996","journal-title":"Am J Gastroenterol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00303.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00303.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1998.00303.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T21:54:46Z","timestamp":1698443686000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1998.00303.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,4]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,4]]}},"alternative-id":["10.1046\/j.1365-2036.1998.00303.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1998.00303.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,4]]}}}